Related Experiment Video
Updated: Jun 24, 2026
09:07
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
COMT val158met influence on electroconvulsive therapy response in major depression.
Katharina Domschke1, Maxim Zavorotnyy, Julia Diemer
1Department of Psychiatry, University of Muenster, Muenster, Germany. katharina.domschke@ukmuenster.de
Summary
The catechol-O-methyltransferase (COMT) val158met gene variation impacts electroconvulsive therapy (ECT) response in women with treatment-resistant depression. The COMT 158val allele is linked to more severe depression but better ECT outcomes.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Depression pathogenesis has a significant genetic component.
- The catechol-O-methyltransferase (COMT) val158met polymorphism is a potential genetic susceptibility factor.
- Understanding genetic influences on treatment response is crucial for personalized medicine.
Purpose of the Study:
- To investigate the effect of the COMT val158met polymorphism on electroconvulsive therapy (ECT) response.
- To analyze the association between COMT genotype and depression severity and treatment outcomes.
- To explore potential gender-specific effects of COMT variation on ECT efficacy.
Main Methods:
- Analysis of 104 Caucasian patients with pharmacologically treatment-resistant Major Depression.
- Genotyping for the COMT val158met polymorphism.
- Assessment of depression severity and ECT treatment response, including core and sleep-related symptoms.
Main Results:
- The higher activity COMT 158val allele was associated with higher pre-ECT depression severity.
- Carriers of the COMT 158val allele showed better treatment response to ECT, especially for core and sleep symptoms.
- These associations were significant only within the female subgroup.
Conclusions:
- COMT gene variation has a gender-specific impact on electroconvulsive therapy response.
- COMT 158val allele carriers may experience more severe, treatment-resistant depression, potentially benefiting more from ECT.
- Findings support the role of genetic factors in predicting ECT efficacy in specific patient populations.
Related Concept Videos
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Depressive Disorders: Etiology
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...